Signal26 Biotherapeutics is a biotechnology startup dedicated to advancing a novel antibody for treating psoriasis. In collaboration with interdisciplinary experts, we lead research into interleukin 26 (IL-26) and its role in the signalling pathways involved in autoimmune disorders.
Some insights
Our team is specialised in pre-clinical research, CMC development, and analytical methods. As we progress to the clinical phase, we are looking for clinical and regulatory experts to join the team.